Filing Details
- Accession Number:
- 0001415889-24-023094
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-09-09 21:20:12
- Reporting Period:
- 2024-09-05
- Accepted Time:
- 2024-09-09 21:20:12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1438533 | Travere Therapeutics Inc. | TVTX | Pharmaceutical Preparations (2834) | 262383102 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1763494 | M Eric Dube | C/O Travere Therapeutics, Inc. 3611 Valley Centre Dr., Suite 300 San Diego CA 92130 | Chief Executive Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-09-05 | 32,500 | $0.00 | 383,100 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2024-09-09 | 21,125 | $11.52 | 361,975 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Footnotes
- On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 32,500 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy.
- This sale was made pursuant to a written plan adopted on March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
Billionaire Hedge Funds
